Get the Stockscreener App
2.44
0.41%
-0.01
After Hours:
2.45
0.01
+0.41%
Anebulo Pharmaceuticals Inc stock is traded at $2.44, with a volume of 45,743.
It is down -0.41% in the last 24 hours and down -9.63% over the past month.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
See More
Previous Close:
$2.45
Open:
$2.44
24h Volume:
45,743
Relative Volume:
0.34
Market Cap:
$100.25M
Revenue:
-
Net Income/Loss:
$-7.92M
P/E Ratio:
-8.1333
EPS:
-0.3
Net Cash Flow:
$-7.05M
1W Performance:
-1.21%
1M Performance:
-9.63%
6M Performance:
+59.48%
1Y Performance:
+31.89%
1-Day Range:
$2.39
$2.49
1-Week Range:
$2.38
$2.60
52-Week Range:
$0.8001
$3.39
Anebulo Pharmaceuticals Inc Stock (ANEB) Company Profile
Name
Anebulo Pharmaceuticals Inc
Sector
Industry
Phone
737 203 5270
Address
C/O ANEBULO PHARMACEUTICALS, INC., LAKEWAY
Compare ANEB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANEB
Anebulo Pharmaceuticals Inc
|
2.44 | 100.66M | 0 | -7.92M | -7.05M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Anebulo Pharmaceuticals Inc Stock (ANEB) Latest News
Anebulo begins phase 1 trial of IV cannabis toxicity treatment - Investing.com
First-Ever Emergency Cannabis Toxicity Antidote: Anebulo's IV Drug Enters Phase 1 Trial with NIDA Grant - Stock Titan
Anebulo Pharmaceuticals Inc. stock momentum explainedExit Point & AI Powered Buy/Sell Recommendations - newser.com
What institutional flow reveals about Anebulo Pharmaceuticals Inc.July 2025 WrapUp & Reliable Entry Point Trade Alerts - newser.com
Published on: 2025-09-24 05:39:09 - newser.com
Published on: 2025-09-23 19:22:34 - newser.com
Anebulo Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Macro Moves & Safe Entry Momentum Tips - newser.com
Institutional scanner results for Anebulo Pharmaceuticals Inc.Day Trade & Community Consensus Stock Picks - newser.com
Does Anebulo Pharmaceuticals Inc. fit your quant trading modelJuly 2025 Recap & Weekly Market Pulse Alerts - newser.com
Visualizing Anebulo Pharmaceuticals Inc. stock with heatmapsTrade Signal Summary & Consistent Return Strategy Ideas - newser.com
Can Anebulo Pharmaceuticals Inc. recover in the next quarterGap Down & Entry and Exit Point Strategies - newser.com
Will breakout in Anebulo Pharmaceuticals Inc. lead to full recoveryWeekly Risk Summary & Safe Capital Growth Stock Tips - newser.com
Is it time to cut losses on Anebulo Pharmaceuticals Inc.Portfolio Gains Summary & Breakout Confirmation Alerts - newser.com
Trading Recap: What are Anebulo Pharmaceuticals Incs earnings expectationsMarket Trend Report & AI Enhanced Trade Execution Alerts - خودرو بانک
Anebulo Pharmaceuticals (ANEB) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
When is the best time to exit Anebulo Pharmaceuticals Inc.Quarterly Investment Review & Weekly Breakout Stock Alerts - newser.com
Is Anebulo Pharmaceuticals Inc. stock reversal real or fakeTrade Risk Summary & Stepwise Entry and Exit Trade Signals - newser.com
Anebulo approves reverse stock split ahead of going-private transaction - MSN
What’s next for Anebulo Pharmaceuticals Inc. stock priceQuarterly Earnings Report & Fast Exit and Entry Trade Guides - newser.com
Published on: 2025-09-19 14:00:51 - newser.com
Is Anebulo Pharmaceuticals Inc. forming a reversal pattern2025 Price Targets & Weekly High Momentum Picks - newser.com
Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It - Benzinga
S P Trends: Whats the beta of Anebulo Pharmaceuticals Inc stockTrade Risk Summary & Growth Focused Investment Plans - خودرو بانک
Anebulo Pharmaceuticals Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Aug Highlights: What are Anebulo Pharmaceuticals Incs earnings expectations2025 Dividend Review & Precise Swing Trade Alerts - خودرو بانک
Aug Setups: What are Anebulo Pharmaceuticals Incs earnings expectations2025 Price Targets & Fast Exit/Entry Strategy Plans - خودرو بانک
Decliners Report: Can Anebulo Pharmaceuticals Inc withstand a market correction2025 Market Trends & Daily Chart Pattern Signal Reports - خودرو بانک
Weekly Earnings: Is Anebulo Pharmaceuticals Inc. stock heavily shortedJuly 2025 Spike Watch & Smart Allocation Stock Reports - خودرو بانک
Market Outlook: Will Anebulo Pharmaceuticals Inc benefit from green energy policies2025 Macro Impact & AI Driven Price Forecasts - خودرو بانک
Analyst Calls: Is Anebulo Pharmaceuticals Inc a good ESG investment2025 Fundamental Recap & AI Powered Market Entry Strategies - خودرو بانک
Geopolitics Watch: Why is Anebulo Pharmaceuticals Inc stock going downJuly 2025 Patterns & Entry Point Strategy Guides - خودرو بانک
Resistance Check: Will Anebulo Pharmaceuticals Inc outperform small cap indexesTrade Exit Summary & Verified Momentum Watchlists - خودرو بانک
Leading vs lagging indicators on Anebulo Pharmaceuticals Inc. performanceJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
CEO Change: Is Anghami Inc. Equity Warrant stock good for income investors - khodrobank.com
Can swing trading help recover from Anebulo Pharmaceuticals Inc. lossesDividend Hike & AI Driven Stock Reports - newser.com
Anebulo Pharmaceuticals Inc Stock (ANEB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):